<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37169">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02622659</url>
  </required_header>
  <id_info>
    <org_study_id>2012Pro170EKZY</org_study_id>
    <nct_id>NCT02622659</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Influenza (Acute Upper Respiratory Infection)</brief_title>
  <official_title>The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Influenza (Acute Upper Respiratory Infection)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Yipinhong Pharmaceutical CO.,LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Yipinhong Pharmaceutical CO.,LTD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double blind, double dummy, positive drug parallel comparison, multi-centre
      clinical trial to assess the efficacy and safety of Fuganlin Oral Liquid in children with
      influenza (acute upper respiratory infection).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment group: Fuganlin Oral Liquid 10mL. Control group: Xiaoer Jiebiao oral liquid 100mL.
      Treatment for one week. Patients who were recovered within one week can withdrawal at any
      time.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The duration of cold symptoms</measure>
    <time_frame>Defined as the time from the onset of the cold to the time achieve a cold cure standard，time average 3 to 7 days</time_frame>
    <description>Cold diagnostic criteria：
nasal congestion, runny nose, sneezing, itchy throat, or pain, cough
The chills, fever, no sweat or less sweat, headache, limb sour
The total number normal or low of white blood cells, neutropenia, relative increase in lymphocytes
Cold cure criteria:
fever, aversion to wind individual symptoms disappeared
nasal congestion, runny nose, sore throat, cough individual symptoms disappeared</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">468</enrollment>
  <condition>Acute Upper Respiratory Infection</condition>
  <arm_group>
    <arm_group_label>Fuganlin Oral Liquid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fuganlin Oral Liquid:oral
less than 1 years old: 5mL each time and three times a day
1~3 years old: 10mL each time and three times a day
4~6 years old: 10mL each time and four times a day
7~12 years old: 10mL each time and five times a day
Xiaoer Jiebiao Oral Liquid placebo:oral
1~2 years old: 5mL each time and twice a day
3~5 years old: 5mL each time and three times a day
6~14 years old: 10mL each time and twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xiaoer Jiebiao Oral Liquid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xiaoer Jiebiao Oral Liquid:oral
1~2 years old: 5mL each time and twice a day
3~5 years old: 5mL each time and three times a day
6~14 years old: 10mL each time and twice a day
Fuganlin Oral Liquid placebo:oral
less than 1 years old: 5mL each time and three times a day
1~3 years old: 10mL each time and three times a day
4~6 years old: 10mL each time and four times a day
7~12 years old: 10mL each time and five times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fuganlin Oral Liquid</intervention_name>
    <description>less than 1 years old: 5mL each time and three times a day
1~3 years old: 10mL each time and three times a day
4~6 years old: 10mL each time and four times a day
7~12 years old: 10mL each time and five times a day</description>
    <arm_group_label>Fuganlin Oral Liquid</arm_group_label>
    <other_name>No other names</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xiaoer Jiebiao Oral Liquid</intervention_name>
    <description>1~2 years old: 5mL each time and twice a day
3~5 years old: 5mL each time and three times a day
6~14 years old: 10mL each time and twice a day</description>
    <arm_group_label>Xiaoer Jiebiao Oral Liquid</arm_group_label>
    <other_name>No other names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients diagnosed as acute upper respiratory infection.

          2. Patients with Traditional Chinese Medicine syndrome of qi deficiency and wind-heat.

          3. Patients aged 1 to 12 years.

          4. With course of disease in 48 hours or less.

          5. Signed informed consent by a Parent or legal guardians.

        Exclusion Criteria:

          1. Patients diagnosed as tonsillitis, bronchitis, bronchiolitis, pneumonia;

          2. Patients have a history of hyperpyretic convulsion;

          3. Severe malnutrition, rickets patients and merge the heart, brain, liver, kidney and
             hematopoietic system and other serious primary diseases;

          4. The increased of serum creatinine (Cr), blood urea nitrogen (BUN), alanine
             aminotransferase (ALT), and urinary protein, urine RBC above &quot;+&quot;, which can not use
             the test illness or possibly combined disease conditions to explain;

          5. Patients with allergic physique (Allergic to above two kinds of substance), allergic
             to the composition of the preparation or control drug;

          6. According to the doctors' determination,likely to loss to follow up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cao xia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chongqing First People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yan yunying, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanning maternal and Child Health Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hu suping, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanchang City Hospital of integrated traditional Chinese and Western Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wang leping, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changzhou traditional Chinese medicine hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liu Dexing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liuzhou traditional Chinese medicine hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qi Shihe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xiangyang Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ding Lijun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Handan traditional Chinese medicine hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yang Liping, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changzhi City People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Feng Ziwei, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Luohe traditional Chinese medicine hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li xinmin, PhD</last_name>
    <phone>0086-022-27432276</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei xiaowei, PhD</last_name>
    <phone>0086-022-27432276</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Luohe traditional Chinese medicine hospital</name>
      <address>
        <city>Luohe</city>
        <state>Henan</state>
        <zip>462000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Ziwei, MD</last_name>
      <phone>0086-0395-2139611</phone>
    </contact>
    <contact_backup>
      <last_name>Tang Yili, MD</last_name>
      <phone>0086-0395-2139611</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>February 14, 2016</lastchanged_date>
  <firstreceived_date>November 16, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute upper respiratory infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
